ArticleFrontiers in immunology2022

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.

Leena Halim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.